A celebrity's recent multiple sclerosis misdiagnosis highlights the complexities of medical liability and the error in judgment defense.

Ursodeoxycholic acid recommended as first-line therapy and to prevent recurrence after liver transplant for PBC.

The sNDA is supported by findings from the phase 3 MANGROVE trial, which demonstrated a 43% reduction in the risk of disease progression or death compared with chemoimmunotherapy in stem cell ...

The designation is based on phase 2 data demonstrating dose-dependent increases in total sleep time among children and adolescents, including those with comorbid neurodevelopmental disorders.

Real-world data show mortality, kidney, and cardiovascular benefits even among those with frailty and multimorbidity.